Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

[1]  W. Nelson,et al.  Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients , 2013, Current medical research and opinion.

[2]  Paul J. Wang,et al.  Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. , 2013, American heart journal.

[3]  T. Gomes,et al.  Persistence with therapy among patients treated with warfarin for atrial fibrillation. , 2012, Archives of internal medicine.

[4]  J. Spertus,et al.  Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians , 2012, Journal of multidisciplinary healthcare.

[5]  G. Lip,et al.  Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.

[6]  A. Amin,et al.  Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. , 2012, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[7]  B. Gersh,et al.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.

[8]  D. Singer,et al.  Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation , 2010, Circulation. Cardiovascular quality and outcomes.

[9]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[10]  J. Plumb,et al.  Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? , 2008, Journal of thrombosis and haemostasis : JTH.

[11]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[12]  M. Rosenqvist,et al.  Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). , 2006, European heart journal.

[13]  Colin Simpson,et al.  Evidence for Age and Sex Differences in the Secondary Prevention of Stroke in Scottish Primary Care , 2005, Stroke.

[14]  M. Ezekowitz,et al.  Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. , 2003, Clinical therapeutics.

[15]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[16]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[17]  S. Connolly,et al.  Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. , 1991, Circulation.

[18]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[19]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[20]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.